The US Food and Drug Administration (FDA) has given Breakthrough Device Designation to Orchestra BioMed for its atrioventricular interval modulation (AVIM) therapy for patients with uncontrolled ...
Background: Dual-chamber pacing is believed to have an advantage over single-chamber ventricular pacing. The aim of the study was to determine whether elderly patients with implanted pacemaker for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback